Avidity Biosciences Introduces Breakthrough Del-zota for the Treatment of Duchenne Muscular Dystrophy
Avidity Biosciences has introduced delpacibart zotadirsen (del-zota) as the first and only investigational therapy to receive FDA Breakthrough Therapy designation for the treatment of Duchenne muscular dystrophy.
Del-zota is designed to deliver a phosphorodiamidate morpholino oligomer (PMO) directly to skeletal and cardiac muscle, where it targets exon 44 of the dystrophin gene. The therapy aims to restore production of near-full length dystrophin, a protein essential for muscle strength and stability, and slow the progression of muscle damage in people living with DMD44.
There are currently no approved therapies that directly target exon 44 skipping in DMD, leaving affected individuals with limited treatment options and a high unmet medical need.
The FDA’s Breakthrough Therapy designation highlights the potential of del-zota to significantly improve clinical outcomes in this population. The therapy has also received Orphan Drug, Rare Pediatric Disease, and Fast Track designations in the United States, along with Orphan Drug designation from the European Medicines Agency (EMA).
Duchenne muscular dystrophy is a rare, progressive condition caused by mutations in the dystrophin gene. It leads to severe muscle weakness, loss of mobility, and eventually affects the heart and respiratory system. The disease primarily affects boys and is typically diagnosed in early childhood.
Del-zota is the first and only investigational therapy to receive U.S. FDA Breakthrough Therapy designation for the treatment of Duchenne muscular dystrophy in individuals with mutations amenable to exon 44 skipping (DMD44).
